Michael Johnson, PhD is a 2017 and 2019 Forbes 30 Under 30 honoree and the CEO and Co-Founder of Visikol Inc., which is a bio-imaging company that spun out of Rutgers University in 2016 and that Michael founded along with his fellow PhD candidate Thomas Villani and colleague Nick Crider. Michael has a diverse background with experiences in both the technical and business considerations of running a biotech business. Following his undergraduate degree in biology at Muhlenberg College, Michael spent three years in various roles at Johnson & Johnson while concurrently pursuing a PhD in applied microbiology at Rutgers University. Michael's research background has focused on a wide-range of projects from remote sensing research with NASA to building light sheet microscopes and producing biofuels. Prior to launching Visikol, Michael worked on several other biotech-based entrepreneurial pursuits and is very passionate about translating cutting edge research into life-changing commercial technologies.
In this webinar, learn about various multiplex labeling (up to 10-plex) techniques and subsequent whole slide imaging approaches from Visikol. Hear how this can be applied to answer complex research questions such as surveying the immune cell population within a tumor microenvironment, or evaluating therapeutics for infectious diseases.
In this webinar, learn about various multiplex labeling (up to 10-plex) techniques and subsequent whole slide imaging approaches from Visikol. Hear how this can be applied to answer complex research questions such as surveying the immune cell population within a tumor microenvironment, or evaluating therapeutics for infectious diseases.
